Mark Prisk – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Mark Prisk on 2016-01-13.
To ask the Secretary of State for Health, if he will assess the effect of individual funding requests for palivizumab on premature babies at risk of severe complications from respiratory syncytial virus.
George Freeman
NHS England has advised that it is monitoring the level of individual funding requests for patients who do not meet the criteria for palivizumab. NHS England aims to finalise an analysis of this data in April 2016 and will report its findings to the neonatal care clinical reference group.
